: A high-risk, high-reward mRNA play with major Phase 2 study results for cystic fibrosis expected in the first half of 2026.
The biotech sector in April 2026 is seeing a resurgence driven by clinical milestones, FDA approvals, and a renewed interest in growth-oriented assets following a period of valuation compression. "Cheap" biotech stocks currently fall into two main categories: those with low nominal share prices (under $10) and larger-cap companies trading at historically low valuation multiples. Promising Stocks Under $10 cheap biotech stocks to buy
: Working on targeted radiotherapy; analysts project significant revenue growth in 2025-2026 if Phase 3 trials succeed. Undervalued Mid-to-Large Cap Leaders : A high-risk, high-reward mRNA play with major
: Analysts view the stock as undervalued, underestimating its core business stability and growth from new product sales. Key 2026 Catalysts to Watch Best Biotech Stocks to Buy for April 2026 Promising Stocks Under $10 : Working on targeted
: Trading at roughly 15 times earnings with double-digit increases in revenue and low debt.